Analysts expect Jernigan Capital, Inc. (NYSE:JCAP) to report $0.15 EPS on February, 28 after the close.They anticipate $0.38 EPS change or 71.70% from last quarter’s $0.53 EPS. JCAP’s profit would be $2.11 million giving it 28.12 P/E if the $0.15 EPS is correct. After having $0.33 EPS previously, Jernigan Capital, Inc.’s analysts see -54.55% EPS growth. The stock decreased 1.63% or $0.28 during the last trading session, reaching $16.87. About 131,632 shares traded. Jernigan Capital, Inc. (NYSE:JCAP) has risen 62.21% since February 22, 2017 and is uptrending. It has outperformed by 45.51% the S&P500.
Foundation Medicine, Inc. provides various molecular information products in the United States. The company has market cap of $2.77 billion. The companyÂ’s molecular information platform includes proprietary methods and algorithms to analyze specimens across various types of cancer, as well as for incorporating that information into clinical care; and offers genomic information about each patientÂ’s individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies. It currently has negative earnings. It provides clinical products, such as FoundationOne for solid tumors; FoundationOne Heme for blood cancers, or hematologic malignancies, including leukemia, lymphoma, and myeloma, as well as sarcomas and pediatric cancers; Foundation Assay for Circulating Tumor; FoundationFocus CDxBRCA, a diagnostic assay to aid in identifying women with ovarian cancer.
Jernigan Capital, Inc. is a New York Stock Exchange-listed real estate investment trust that provides debt and equity capital to private developers, owners, and operators of self-storage facilities. The company has market cap of $237.54 million. Our mission is to be the preeminent capital partner for self-storage entrepreneurs nationwide by offering creative solutions through an experienced team demonstrating the highest levels of integrity, dedication, excellence and community, while maximizing shareholder value. It has a 12.13 P/E ratio. The Jernigan Capital team has extensive experience in over 100 U.S. marketsÂ—from acquiring and managing self-storage properties to new self-storage developmentÂ—providing JCAP with knowledge unmatched by any lender, broker or advisor to the sector.
Among 4 analysts covering Jernigan Capital Inc (NYSE:JCAP), 2 have Buy rating, 1 Sell and 1 Hold. Therefore 50% are positive. Jernigan Capital Inc had 13 analyst reports since August 14, 2015 according to SRatingsIntel. FBR Capital maintained the stock with “Buy” rating in Monday, February 5 report. The company was maintained on Thursday, March 2 by FBR Capital. The stock of Jernigan Capital, Inc. (NYSE:JCAP) has “Outperform” rating given on Thursday, June 23 by FBR Capital. On Wednesday, April 6 the stock rating was downgraded by Wunderlich to “Sell”. The rating was maintained by FBR Capital on Tuesday, May 30 with “Buy”. Jefferies initiated the shares of JCAP in report on Monday, April 24 with “Hold” rating. The rating was maintained by FBR Capital with “Buy” on Friday, December 29. The firm earned “Buy” rating on Tuesday, November 14 by FBR Capital. Wunderlich maintained the shares of JCAP in report on Tuesday, November 10 with “Buy” rating. The firm has “Buy” rating by FBR Capital given on Monday, June 26.
Analysts await Foundation Medicine, Inc. (NASDAQ:FMI) to report earnings on March, 7 after the close. They expect $-1.01 EPS, up 0.98% or $0.01 from last year’s $-1.02 per share. After $-0.90 actual EPS reported by Foundation Medicine, Inc. for the previous quarter, Wall Street now forecasts 12.22% negative EPS growth.
Pier Capital Llc holds 0.98% of its portfolio in Foundation Medicine, Inc. for 140,562 shares. Gilder Gagnon Howe & Co Llc owns 1.52 million shares or 0.86% of their US portfolio. Moreover, Oppenheimer & Co Inc has 0.78% invested in the company for 723,480 shares. The New York-based Needham Investment Management Llc has invested 0.59% in the stock. Ipswich Investment Management Co. Inc., a Massachusetts-based fund reported 14,450 shares.